News coverage about Aeglea BioTherapeutics (NASDAQ:AGLE) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aeglea BioTherapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.0619976370289 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Aeglea BioTherapeutics (NASDAQ:AGLE) traded down 3.10% during midday trading on Tuesday, hitting $4.38. 14,187 shares of the company’s stock traded hands. Aeglea BioTherapeutics has a 52 week low of $2.81 and a 52 week high of $10.34. The company has a 50 day moving average of $4.89 and a 200-day moving average of $4.54. The company’s market capitalization is $72.06 million.

AGLE has been the topic of several analyst reports. Zacks Investment Research cut shares of Aeglea BioTherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. ValuEngine cut shares of Aeglea BioTherapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 6th.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Aeglea BioTherapeutics (AGLE) Stock Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Insider Buying and Selling by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)

Receive News & Stock Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related stocks with our FREE daily email newsletter.